MX2020000386A - Inhibidores heterociclicos de la cinasa atr. - Google Patents
Inhibidores heterociclicos de la cinasa atr.Info
- Publication number
- MX2020000386A MX2020000386A MX2020000386A MX2020000386A MX2020000386A MX 2020000386 A MX2020000386 A MX 2020000386A MX 2020000386 A MX2020000386 A MX 2020000386A MX 2020000386 A MX2020000386 A MX 2020000386A MX 2020000386 A MX2020000386 A MX 2020000386A
- Authority
- MX
- Mexico
- Prior art keywords
- atr kinase
- heterocyclic inhibitors
- inhibitors
- heterocyclic
- atr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531951P | 2017-07-13 | 2017-07-13 | |
| PCT/US2018/042128 WO2019014618A1 (en) | 2017-07-13 | 2018-07-13 | HETEROCYCLIC INHIBITORS OF KINASE ATR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020000386A true MX2020000386A (es) | 2020-08-06 |
Family
ID=64998660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000386A MX2020000386A (es) | 2017-07-13 | 2018-07-13 | Inhibidores heterociclicos de la cinasa atr. |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10392376B2 (enExample) |
| EP (1) | EP3651768B1 (enExample) |
| JP (1) | JP7159307B2 (enExample) |
| KR (1) | KR102676822B1 (enExample) |
| CN (2) | CN117466884B (enExample) |
| AU (1) | AU2018301696B8 (enExample) |
| CA (1) | CA3069693A1 (enExample) |
| DK (1) | DK3651768T3 (enExample) |
| ES (1) | ES2974334T3 (enExample) |
| FI (1) | FI3651768T3 (enExample) |
| HR (1) | HRP20240368T1 (enExample) |
| HU (1) | HUE066043T2 (enExample) |
| IL (1) | IL271930B (enExample) |
| LT (1) | LT3651768T (enExample) |
| MX (1) | MX2020000386A (enExample) |
| PH (1) | PH12020500072A1 (enExample) |
| PL (1) | PL3651768T3 (enExample) |
| PT (1) | PT3651768T (enExample) |
| RS (1) | RS65466B1 (enExample) |
| SI (1) | SI3651768T1 (enExample) |
| SM (1) | SMT202400106T1 (enExample) |
| WO (1) | WO2019014618A1 (enExample) |
| ZA (1) | ZA202000148B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| US10377591B2 (en) | 2017-07-07 | 2019-08-13 | Zebra Technologies Corporation | Input handling for media processing devices |
| HRP20240368T1 (hr) * | 2017-07-13 | 2024-08-30 | Board Of Regents, The University Of Texas System | Heterociklički inhibitori atr kinaze |
| JP7290627B2 (ja) | 2017-08-17 | 2023-06-13 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| JP7235338B2 (ja) * | 2017-09-08 | 2023-03-08 | ニューウェーブ・ファーマスーティカル・インコーポレイテッド | Ａｔｒ阻害剤としての置換ピロロピリジン |
| JP7341156B2 (ja) * | 2018-03-16 | 2023-09-08 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| TW202028209A (zh) * | 2018-09-27 | 2020-08-01 | 大陸商重慶複創醫藥研究有限公司 | 作為RET激酶抑制劑的取代的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶化合物 |
| EP3967694A4 (en) * | 2019-06-06 | 2022-12-07 | Beijing Tide Pharmaceutical Co., Ltd. | 2, 4, 6-TRI-SUBSTITUTED PYRIMIDINE COMPOUND AS ATR-KINASE INHIBITOR |
| CN113121524B (zh) * | 2019-12-31 | 2023-04-25 | 南京创济生物医药有限公司 | 杂环亚砜亚胺化合物及其中间体、制备方法和应用 |
| EP4155307A4 (en) | 2020-05-20 | 2023-09-13 | Beijing Tide Pharmaceutical Co., Ltd. | 2,4,6-TRIS-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS |
| AU2021282122B2 (en) * | 2020-05-29 | 2023-09-21 | Wuxi Life Fountain Biotech Co., Ltd | Fluoropyrrolopyridine compound and application thereof |
| IL299510A (en) * | 2020-07-03 | 2023-02-01 | Antengene Discovery Ltd | Atr inhibitors and uses thereof |
| WO2022171034A1 (zh) * | 2021-02-10 | 2022-08-18 | 江苏先声药业有限公司 | 作为hpk1抑制剂的双环类化合物及其应用 |
| EP4332103A4 (en) * | 2021-05-12 | 2025-09-03 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | ATR INHIBITOR COMPOUND CONTAINING A SULFOXIMINE |
| WO2022262143A1 (zh) * | 2021-06-17 | 2022-12-22 | 杭州中美华东制药有限公司 | 一种吡啶硼酸酯的制备方法 |
| GB2703674A (en) * | 2024-10-14 | 2026-08-05 | Artios Pharma Ltd | Novel composition |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001081338A1 (en) * | 2000-04-25 | 2001-11-01 | Actelion Pharmaceuticals Ltd | Substituted sulfonylaminopyrimidines |
| US7550470B2 (en) * | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
| GB0501999D0 (en) * | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| KR20080083188A (ko) | 2006-01-11 | 2008-09-16 | 아스트라제네카 아베 | 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도 |
| WO2008023159A1 (en) | 2006-08-24 | 2008-02-28 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| CN101563340A (zh) * | 2006-09-14 | 2009-10-21 | 阿斯利康(瑞典)有限公司 | 用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物 |
| JP2008115166A (ja) * | 2006-10-10 | 2008-05-22 | Daiichi Sankyo Co Ltd | ピリジルフェニルメチルスルホン誘導体 |
| JP2010523637A (ja) | 2007-04-12 | 2010-07-15 | エフ．ホフマン−ラ ロシュ アーゲー | 医薬化合物 |
| WO2008144500A2 (en) | 2007-05-17 | 2008-11-27 | Anadys Pharmaceuticals, Inc. | 1-methyl-benzo[1,2,4]thiadiazine, 1-oxide derivatives |
| JP2010533161A (ja) | 2007-07-09 | 2010-10-21 | アストラゼネカ アクチボラグ | 化合物−９４６ |
| JP2010533158A (ja) | 2007-07-09 | 2010-10-21 | アストラゼネカ アクチボラグ | 化合物類−９４５ |
| WO2009007750A1 (en) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k |
| JP2010533159A (ja) * | 2007-07-09 | 2010-10-21 | アストラゼネカ アクチボラグ | 化合物９４７ |
| AU2009220605A1 (en) | 2008-03-06 | 2009-09-11 | Msd K.K. | Alkylaminopyridine derivative |
| CA2728559A1 (en) | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
| KR101712576B1 (ko) * | 2008-11-10 | 2017-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| TW201028410A (en) | 2008-12-22 | 2010-08-01 | Astrazeneca Ab | Chemical compounds 610 |
| WO2010120996A1 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| JP2013032290A (ja) | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | 新規縮合ピリミジン誘導体 |
| WO2011103715A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
| WO2011106276A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
| EP2542536B1 (en) | 2010-03-04 | 2015-01-21 | Cellzome Limited | Morpholino substituted urea derivatives as mtor inhibitors |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| WO2012147890A1 (ja) | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | 新規アゾール誘導体 |
| LT3418281T (lt) | 2012-12-07 | 2021-01-11 | Vertex Pharmaceuticals Inc. | Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| HUE046727T2 (hu) | 2013-12-06 | 2020-03-30 | Vertex Pharma | Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai |
| EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| ES2777608T3 (es) | 2014-06-05 | 2020-08-05 | Vertex Pharma | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo |
| TWI656121B (zh) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| BR112017007708B8 (pt) | 2014-10-13 | 2023-10-24 | Atrin Pharmaceuticals LLC | Composto macrocíclico e composição farmacêutica |
| WO2017210545A1 (en) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| HRP20240368T1 (hr) | 2017-07-13 | 2024-08-30 | Board Of Regents, The University Of Texas System | Heterociklički inhibitori atr kinaze |
| JP7290627B2 (ja) | 2017-08-17 | 2023-06-13 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| JP7341156B2 (ja) | 2018-03-16 | 2023-09-08 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
-
2018
- 2018-07-13 HR HRP20240368TT patent/HRP20240368T1/hr unknown
- 2018-07-13 ES ES18831104T patent/ES2974334T3/es active Active
- 2018-07-13 CN CN202311427557.9A patent/CN117466884B/zh active Active
- 2018-07-13 RS RS20240297A patent/RS65466B1/sr unknown
- 2018-07-13 CN CN201880051484.9A patent/CN111867590B/zh active Active
- 2018-07-13 HU HUE18831104A patent/HUE066043T2/hu unknown
- 2018-07-13 KR KR1020207004080A patent/KR102676822B1/ko active Active
- 2018-07-13 SM SM20240106T patent/SMT202400106T1/it unknown
- 2018-07-13 DK DK18831104.7T patent/DK3651768T3/da active
- 2018-07-13 IL IL271930A patent/IL271930B/en unknown
- 2018-07-13 FI FIEP18831104.7T patent/FI3651768T3/fi active
- 2018-07-13 SI SI201831077T patent/SI3651768T1/sl unknown
- 2018-07-13 PL PL18831104.7T patent/PL3651768T3/pl unknown
- 2018-07-13 WO PCT/US2018/042128 patent/WO2019014618A1/en not_active Ceased
- 2018-07-13 US US16/035,310 patent/US10392376B2/en active Active
- 2018-07-13 MX MX2020000386A patent/MX2020000386A/es unknown
- 2018-07-13 EP EP18831104.7A patent/EP3651768B1/en active Active
- 2018-07-13 PT PT188311047T patent/PT3651768T/pt unknown
- 2018-07-13 JP JP2020523235A patent/JP7159307B2/ja active Active
- 2018-07-13 LT LTEPPCT/US2018/042128T patent/LT3651768T/lt unknown
- 2018-07-13 AU AU2018301696A patent/AU2018301696B8/en active Active
- 2018-07-13 CA CA3069693A patent/CA3069693A1/en active Pending
-
2019
- 2019-07-10 US US16/507,851 patent/US10800769B2/en active Active
-
2020
- 2020-01-09 ZA ZA2020/00148A patent/ZA202000148B/en unknown
- 2020-01-09 PH PH12020500072A patent/PH12020500072A1/en unknown
- 2020-09-01 US US17/009,428 patent/US11434233B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018003511A1 (es) | Derivados de pirazolopirimidina como inhibidor de quinasa. | |
| ZA202000148B (en) | Heterocyclic inhibitors of atr kinase | |
| CL2019002304A1 (es) | Compuestos para el tratamiento del cáncer. | |
| ECSP17029203A (es) | Inhibidor de cinasa aurora a | |
| ECSP19045511A (es) | Composiciones y métodos para inhibir la acción de la arginasa | |
| CL2019001551A1 (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
| CL2019000511A1 (es) | Inhibidores de procesos metabólicos celulares. | |
| CL2016001082A1 (es) | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa | |
| CL2017002786A1 (es) | Referencia cruzada a solicitudes relacionadas | |
| MX394062B (es) | Métodos para el tratamiento del cáncer ovárico. | |
| CL2016000045A1 (es) | Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cáncer. | |
| MX2016002137A (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| PT3119762T (pt) | Derivados de benzimidazole como inibidores de tirosina quinase erbb para o tratamento do cancro | |
| MX2016014253A (es) | Inhibidores de desmetilasa-1 especifica de lisina. | |
| EA201591509A1 (ru) | Ингибиторы cdc7 | |
| MX2015011281A (es) | Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. | |
| CL2019002557A1 (es) | Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1. | |
| MX2017001352A (es) | Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2). | |
| MX2017009246A (es) | Farmaco de combinacion. | |
| CL2017000006A1 (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| MX2019010595A (es) | Derivados de pirrolotriazina como inhibidores de cinasas. | |
| MX2019002673A (es) | Composiciones y metodos para tratar demencia. | |
| DOP2017000136A (es) | Compuestos para tratar el cáncer | |
| MX2019003311A (es) | Metodos para tratamiento de cancer de ovario. | |
| AR106772A1 (es) | Sales de (s)-lactato |